Screening for Antibodies (IgG) to the COVID-19 virus infection
Diagnosing the COVID-19 viral infection relies on two major methodologies: 1) identification of the viral RNA (antigen) using polymerase chain reaction analysis, and 2) serological immunoassays that detect the viral-specific antibody IgG.
Screening for COVID-19 RNA uses nasopharyngeal swabs. It identifies the active virus or proteins associated with the virus. This is called an “antigen” test. As the clinical symptoms resolve, the amount of COVID-19 virus being shed tends to decrease, and RNA antigen tests often become negative.
COVID-19 IgG antibody generally first appears 10 days to two weeks after COVID-19 infection starts – often around the time symptoms of infection, if there were any, improve. This is important because the presence of COVID19 IgG antibody may indicate immunity to future COVID-19 infections.
That is why EnMed MicroAnalytics also is committed to working hard and staying up with the latest COVID-19 antibody literature – and notifying you, as soon as more is known about COVID-19 immunity.